Bota Biosciences Releases BPL, a Compiler-Verified Protocol Language for AI-Driven Biomanufacturing
Biological protocols today still rely on natural language — instructions like "resuspend in an appropriate volume" leave concentration, duration, and technique unstated. A 2016 survey of 1,576 researchers found more than 70% had failed to reproduce another scientist's experiments. Semiconductor design resolved an analogous problem through Verilog and VHDL; software engineering through typed, compiler-verified languages. Biology has lacked an equivalent — and that absence is now the rate-limiting step between AI-driven experimental design and reproducible physical execution.
BPL introduces a biology-native type system in which every quantity carries physical units, every reagent declares its physical form, and every container maintains compiler-tracked state — rejecting physically impossible operations before any experiment begins. BPL-COGEN automates the translation from natural-language SOPs to verified BPL code via a generate–validate–repair loop, coupling a fine-tuned 30-billion-parameter language model with a deterministic compiler. Evaluated against 300 published Nature Protocols papers, the system achieved 95.1% first-pass consistency, advancing to 98.6% after two rounds of compiler-simulation feedback. Cross-platform validation confirmed reproducible execution across manual and automated contexts. Source code is available on GitLab under the MIT License.
As the execution layer of Bota's world-leading Physical AI-driven biofoundry platform
View original content:https://www.prnewswire.com/news-releases/bota-biosciences-releases-bpl-a-compiler-verified-protocol-language-for-ai-driven-biomanufacturing-302807351.html
SOURCE Bota Biosciences
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zhong Baoshen at 2026 Annual Meeting of the New Champions: Solar-Plus-Storage Integration Breaks the Boundaries of Global Green Energy Application
- Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
- Circulate Health announces exclusive partnership with Reborne to bring its advanced therapeutic plasma exchange protocols to UK for first time
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share